Nebulized corticosteroids in the management of acute exacerbation of COPD

Lung India

Volumn 27, Issue 4, 2010, Pages 230-235

  Gaude, G S ^a   Nadagouda, S ^a  

^a JAWAHARLAL NEHRU MEDICAL COLLEGE   (India)

Author keywords

Budesonide; COPD; corticosteroids; exacerbation; nebulized steroids

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; IPRATROPIUM BROMIDE; PLACEBO; PREDNISOLONE;

APPETITE; ASTHMA; AVASCULAR NECROSIS; BLOOD PRESSURE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; EMBASE; EYE DISEASE; GLAUCOMA; GROWTH RETARDATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INSOMNIA; MEDLINE; MOOD CHANGE; MUSCLE WEAKNESS; NEBULIZATION; OSTEOPOROSIS; PEPTIC ULCER; REVIEW; SIDE EFFECT; SLEEP DISORDER; SODIUM RETENTION; STEROID URINE LEVEL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 78149401472     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.71957     Document Type: Review

References (31)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD).TM Global strategy for agnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; 2009.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
4. Third National Health and Nutrition Examination Survey (NHANES III) Public-Use Data Files. Hattsville: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.
5. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbation of COPD. Ann Intern Med 1987;166:196-204.
6. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
7. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-5.
8. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the lung health study. Am J Respir Crit Care Med 2001;164:358-64.
9. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.
10. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild to moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.
11. Pauwells RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): Hypothesis and design. Eur Respir J 1992;5:1254-61.
12. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
13. Singh JM, Pada VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbation of chronic obstructive pulmonary disease. Arch Intern Med 2002;162:2527-36.
14. Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci 1998;94:557-72.
15. Gunen H, Mirici A, Meral M, Akgun M. Steroids in acute exacerbations of chronic obstructive pulmonary disease: Are nebulized and systemic forms comparable? Curr Opin Pulm Med 2009;15:133-7.
16. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009;374:668-70.
17. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-29.
18. Novak B. The role of corticosteroids in acute exacerbations of chronic obstructive pulmonary disease. Crit Care Nurse 2002;22:80-1.
19. Yang IA, Fong K, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database System Rev 2007;2:CD002991.
20. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: A systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253-62.
21. Mitchell CE, Alpers JH, Morton SM, Baggoley CJ, Croker WD, Walsh AJ, et al, Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur Respir J 1995;8:S490.
22. Matthews EE, Curtis PD, McLain BI, Morris LS, Turbitt ML. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999;88:841-3.
23. Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999;88:835-40.
24. Morice AH, Morris D, Lawson-Matthew P. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996;60:675-8.
25. Maltais F, Ostinelli J, Bourbeau J, Tonnel A, Jacquemet N, Haddon J, et al, Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:698-703.
26. Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest 2003;23:55-62.
27. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007;30:399-400. (Pubitemid 47194198)
28. Wei H, Xin Z. Nebulised budesonide in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Practical Clin Med Mag 2004. p. 3. [last cited on 2004]; Available from: http://www.scholar.ilib.cn/A- jslcyxzz200402003.html [last accessed on 2009 Oct 25].
29. Guozhong C, Wen X, Qi Z, Liang Z, Guozhong C, Huiwen XU, et al, The effect of inhaled budesonide in persons with acute exacerbations of chronic obstructive pulmonary disease. Chinese General Medicine 2005. p. 3. [last cited on 2005]; Available from: http://www.scholar.ilib.cn/A-zgqkyx200520011.html [last accessed on 2009 Oct 25].
30. Marcus P. Budesonide inhalation suspension in adults with poorly controlled asthma or chronic obstructive pulmonary disease. J Appl Res 2009;9:3-13.
31. Gaude GS, Nemagouda S. Clinical efficacy of nebulized budesonide with parental/oral steroids in patients with acute exacerbation of COPD: A prospective study in tertiary care hospital. Lung India 2009;26:S11-2.